PMID: 11342197May 9, 2001Paper

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
C VogelS J. Stewart

Abstract

Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin(R) (trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer who had relapsed after one or two chemotherapy regimens for their metastatic disease. The results showed a positive and durable overall response rate (15% according to a response evaluation committee (REC) assessment) using trastuzumab monotherapy (initial dose 4 mg/kg intravenously (i.v.) followed by 2 mg/kg i.v. weekly). In another recently completed phase II trial, 113 patients were randomised to two dose levels (initial dose of 4 mg/kg i.v. dose followed by 2 mg/kg i.v. weekly, or initial dose of 8 mg/kg followed by 4 mg/kg i.v. weekly) of single-agent trastuzumab as first-line therapy for metastatic disease. The preliminary overall response rate was 23% based on investigator assessment, and tolerability was excellent as in previous trials; efficacy was similar in both dose groups, but the side-effects tended to be more frequent in the higher dose group. The preferred dosage is therefore the same as that currently recommended, i.e. an initial dose of 4 mg/kg i.v. followed by...Continue Reading

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Sep 1, 1993·Cancer Immunology, Immunotherapy : CII·G D LewisH M Shepard

❮ Previous
Next ❯

Citations

Jan 21, 2010·Cancer Chemotherapy and Pharmacology·April DavoliThomas L Brown
Feb 5, 2008·Journal of Mammary Gland Biology and Neoplasia·Charles V ClevengerFeng Fang
Mar 5, 2004·Surgical Oncology·Soo Lo, Stephen R D Johnston
May 9, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J Baselga
Jul 27, 1999·The Journal of Steroid Biochemistry and Molecular Biology·M Roach
Apr 13, 2002·Journal of the American College of Surgeons·Funda MericKelly K Hunt
Nov 20, 2004·Immunology and Cell Biology·Circe Mesa, Luis E Fernández
Jan 1, 2008·Breast Care·Christian JackischAxel Ullrich
Apr 30, 2008·International Seminars in Surgical Oncology : ISSO·Ashok Subramanian, Kefah Mokbel
May 21, 2004·American Journal of Clinical Pathology·Kenneth Bloom, Douglas Harrington
Dec 6, 2006·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Yasuhiro TsutaniShigemitsu Takashima
Mar 19, 2014·Cancers·Lori E Lowes, Alison L Allan
Aug 2, 2001·Seminars in Pediatric Surgery·A M Davidoff, D A Hill
Jun 14, 2002·Seminars in Oncology·Daniel F Hayes, Ann D Thor
Jan 16, 2008·Expert Opinion on Biological Therapy·Giuseppe ToniniDaniele Santini
Oct 6, 2005·Cancer Investigation·Tarun Wasil, Stuart M Lichtman
Nov 18, 2003·The Breast Journal·Charles L Vogel, Sandra X Franco
Jul 29, 2006·Expert Opinion on Pharmacotherapy·Jan Norum
Oct 2, 2003·Expert Opinion on Biological Therapy·L H Stockwin, S Holmes
Apr 5, 2007·Molecular Cancer·William C S Cho
Oct 16, 2008·BMC Cancer·Rachel E EllsworthCraig D Shriver
May 22, 2007·Breast Cancer Research : BCR·Coya TapiaLukas Bubendorf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.